Abstract: In certain embodiments, this disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a compound of Formula I or derivatives thereof, as described herein, to a subject in need thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.

Abstract: In certain embodiments, this disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of 1,1?-(dodecane-1,12-diyl)bis(cyclopropane-1-carboxamide), pharmaceutical salts or derivatives thereof, as described herein, to a subject in need thereof. in certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.

Abstract: This disclosure relates to methods of managing polyuria as a side effect of vasopressin receptor antagonist therapies. In certain embodiments, this disclosure relates to methods of treating or preventing polyuria as a side effect of a vasopressin receptor antagonist therapy comprising administering a vasopressin receptor antagonist to a human subject in combination with an effective amount of an activator of adenosine monophosphate activated protein kinase (AMPK). In certain embodiments, the subject is diagnosed with autosomal dominant polycystic kidney disease (ADPKD). In certain embodiments, the subject is diagnosed with polyuria.

Abstract: In certain embodiments, this disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a compound of Formula I or derivatives thereof, as described herein, to a subject in need thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.

Abstract: In certain embodiments, this disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a compound of Formula (I) or derivatives thereof, as described herein, to a subject in need thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.

Abstract: In certain embodiments, this disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a compound of Formula (I) or derivatives thereof, as described herein, to a subject in need thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.

Abstract: Methods of biological control of agricultural insect pests are disclosed. These methods utilize biological control agents which are genetically altered strains of root-colonizing strains of members of the species P. cepacia. These strains are genetically altered by introduction of genes encoding insect toxic crystal proteins, and are thereby rendered insect toxic. Genetically altered insect toxic bacterial strains are also provided.

Abstract: The compound 5-hydroxy-4-methyl-3-heptanone (sitophilure) having the structural formula ##STR1## has been identified as an aggregation pheromone for both males and females of grain weevils belonging to the genus Sitophilus. The compound and compositions containing the same are useful tools for the monitoring and control of these major agricultural pests of stored grain.